PB 148 of 2025
National Health (Minimum Stockholding) Amendment Determination (No. 11) 2025
I, Rebecca Richardson, as delegate of the Minister for Health and Ageing, make the following determination.
Dated 25 November 2025
Rebecca Richardson
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing
1 Name
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments commencing 1 December 2025
National Health (Minimum Stockholding) Determination 2023
(1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 11) 2025.
(2) This instrument may also be cited as PB 148 of 2025.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 December 2025. | 1 December 2025 |
2. Schedule 1 | 1 December 2025. | 1 December 2025 |
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
1 Schedule 1 (table)
After:
Amisulpride | Oral solution 100 mg per mL, 60 mL | Oral | Solian Solution | 4 months stock by reference to usual PBS demand |
insert:
Amisulpride | Tablet 100 mg | Oral | AMISULPRIDE-WGR | between 1 December 2025 to 30 April 2026—0 months stock by reference to usual demand |
2 Schedule 1 (table)
After:
Amlodipine | Tablet 5 mg (as besilate) | Oral | APX-AMLODIPINE | 6 months stock by reference to usual demand of both Amlodipine APOTEX and APX-AMLODIPINE added together |
insert:
Amoxicillin | Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | Oral | NOUMED AMOXICILLIN | between 1 December 2025 to 31 January 2026—0 months stock by reference to usual demand |
3 Schedule 1 (table)
After:
Atropine | Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL | Injection | Atropine Injection (Bridgewest) | (a) between 1 April 2025 and 30 September 2025—6 months stock by reference to usual PBS demand of the brand Atropine Injection (Pfizer) (b) between 1 October 2025 and 31 March 2026—6 months stock by reference to usual PBS demand of both Atropine Injection (Pfizer) and Atropine Injection (Bridgewest) added together (c) after 31 March 2026—6 months stock by reference to usual PBS demand |
insert:
Azathioprine | Tablet 25 mg | Oral | NOUMED AZATHIOPRINE | between 1 December 2025 to 31 January 2026—0 months stock by reference to usual demand |
Azathioprine | Tablet 50 mg | Oral | NOUMED AZATHIOPRINE | between 1 December 2025 to 31 January 2026—0 months stock by reference to usual demand |
4 Schedule 1 (table)
Omit:
Flucloxacillin | Powder for injection 1 g (as sodium monohydrate) | Injection | Flucil | between 1 October 2025 to 30 November 2025—0 months stock by reference to usual demand |
5 Schedule 1 (table)
Omit:
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Fluoxetine APOTEX | between 1 June 2025 and 30 November 2025—0 months stock by reference to usual demand |
6 Schedule 1 (table)
Omit:
Imatinib | Capsule 400 mg (as mesilate) | Oral | Imatinib-APOTEX | 3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together |
7 Schedule 1 (table)
After:
Levetiracetam | Tablet 1 g | Oral | LEVETIRACETAM-WGR | 6 months stock by reference to usual demand |
insert:
Levetiracetam | Tablet 1 g | Oral | NOUMED LEVETIRACETAM | between 1 December 2025 to 28 February 2026—0 months stock by reference to usual demand |
8 Schedule 1 (table)
After:
Levetiracetam | Tablet 250 mg | Oral | Levetiracetam Viatris | after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together |
insert:
Levetiracetam | Tablet 250 mg | Oral | NOUMED LEVETIRACETAM | between 1 December 2025 to 28 February 2026—0 months stock by reference to usual demand |
Levetiracetam
| Tablet 500 mg | Oral | NOUMED LEVETIRACETAM | between 1 December 2025 to 28 February 2026—0 months stock by reference to usual demand |
9 Schedule 1 (table)
Omit:
Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | Molaxole | between 1 November 2025 to 30 November 2025—0 months stock by reference to usual demand |
10 Schedule 1 (table)
After:
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | APX-PANTOPRAZOLE | 6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together |
insert:
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | NOUMED PANTOPRAZOLE | between 1 December 2025 to 31 January 2026—0 months stock by reference to usual demand |
11 Schedule 1 (table)
Omit:
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Pariet | between 1 June 2025 and 30 November 2025—0 months stock by reference to usual demand |
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Pariet | between 1 June 2025 and 30 November 2025—0 months stock by reference to usual demand |
12 Schedule 1 (table)
After:
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Parbezol | 4 months stock by reference to usual demand |
insert:
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | NOUMED RABEPRAZOLE | between 1 December 2025 to 31 January 2026—0 months stock by reference to usual demand |
13 Schedule 1 (table)
Omit:
Risperidone | Tablet 0.5 mg | Oral | NOUMED RISPERIDONE | between 1 August 2025 and 30 November 2025—0 months stock by reference to usual demand |
14 Schedule 1 (table)
After:
Sevelamer | Tablet containing sevelamer carbonate 800 mg | Oral | ARX-SEVELAMER | 4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together |
insert:
Sildenafil | Tablet 20 mg (as citrate) | Oral | Revatio | between 1 December 2025 to 31 January 2026—0 months stock by reference to usual demand |
15 Schedule 1 (table)
Omit:
Tobramycin | Solution for inhalation 300 mg in 5 mL | Inhalation | Tobramycin WKT | between 1 October 2025 to 30 November 2025—0 months stock by reference to usual demand |